Last reviewed · How we verify

Acetyl-L-Carnitine

Dong-A ST Co., Ltd. · FDA-approved active Small molecule

Acetyl-L-Carnitine is a Amino acid derivative / Metabolic agent Small molecule drug developed by Dong-A ST Co., Ltd.. It is currently FDA-approved for Age-related cognitive decline, Mild cognitive impairment, Peripheral neuropathy. Also known as: Nicetile, Chinese Food and Drug Administration H20180021, ALCAR, ALC.

Acetyl-L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, enhancing cellular energy production.

Acetyl-L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, thereby enhancing cellular energy production. Used for Age-related cognitive decline, Mild cognitive impairment, Peripheral neuropathy.

At a glance

Generic nameAcetyl-L-Carnitine
Also known asNicetile, Chinese Food and Drug Administration H20180021, ALCAR, ALC
SponsorDong-A ST Co., Ltd.
Drug classAmino acid derivative / Metabolic agent
TargetCarnitine palmitoyltransferase (CPT) system
ModalitySmall molecule
Therapeutic areaNeurology, Geriatrics, Metabolic disorders
PhaseFDA-approved

Mechanism of action

Acetyl-L-Carnitine is an acetylated form of L-carnitine that plays a crucial role in mitochondrial fatty acid metabolism. It acts as a carrier molecule that transports activated long-chain fatty acids across the inner mitochondrial membrane, enabling their oxidation to generate ATP. Additionally, acetyl-L-carnitine serves as an acetyl donor and may have neuroprotective and cognitive-enhancing properties through multiple pathways including acetylcholine synthesis and antioxidant effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Acetyl-L-Carnitine

What is Acetyl-L-Carnitine?

Acetyl-L-Carnitine is a Amino acid derivative / Metabolic agent drug developed by Dong-A ST Co., Ltd., indicated for Age-related cognitive decline, Mild cognitive impairment, Peripheral neuropathy.

How does Acetyl-L-Carnitine work?

Acetyl-L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, enhancing cellular energy production.

What is Acetyl-L-Carnitine used for?

Acetyl-L-Carnitine is indicated for Age-related cognitive decline, Mild cognitive impairment, Peripheral neuropathy, Fatigue and energy metabolism disorders.

Who makes Acetyl-L-Carnitine?

Acetyl-L-Carnitine is developed and marketed by Dong-A ST Co., Ltd. (see full Dong-A ST Co., Ltd. pipeline at /company/dong-a-st-co-ltd).

Is Acetyl-L-Carnitine also known as anything else?

Acetyl-L-Carnitine is also known as Nicetile, Chinese Food and Drug Administration H20180021, ALCAR, ALC.

What drug class is Acetyl-L-Carnitine in?

Acetyl-L-Carnitine belongs to the Amino acid derivative / Metabolic agent class. See all Amino acid derivative / Metabolic agent drugs at /class/amino-acid-derivative-metabolic-agent.

What development phase is Acetyl-L-Carnitine in?

Acetyl-L-Carnitine is FDA-approved (marketed).

What are the side effects of Acetyl-L-Carnitine?

Common side effects of Acetyl-L-Carnitine include Gastrointestinal upset, Nausea, Headache, Insomnia, Body odor (fish-like).

What does Acetyl-L-Carnitine target?

Acetyl-L-Carnitine targets Carnitine palmitoyltransferase (CPT) system and is a Amino acid derivative / Metabolic agent.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing